IBD Donor Cells for Translational Immunology and Drug Development
Inflammatory bowel disease — Crohn’s disease and ulcerative colitis — is a high-activity therapeutic area with significant unmet need despite multiple approved biologic and small molecule therapies. The IL-12/IL-23/Th1/Th17 axis, integrin-mediated lymphocyte trafficking, and JAK-STAT signaling are all validated targets in IBD, yet a substantial proportion of patients fail or lose response to current therapies.
OrganaBio IBD and Crohn’s disease donors provide peripheral blood PBMCs with clinical annotation for research applications in this indication. All material is for research use only (RUO).
IBD Immune Biology: What Makes These Donors Relevant
Th1/Th17 axis dysregulation
Crohn’s disease is classically associated with Th1 (IFN-gamma, TNF) and Th17 (IL-17A, IL-17F, IL-22) pathway overactivation in the intestinal mucosa, reflecting dysregulated responses to luminal microbiota. Peripheral blood T cells from active Crohn’s patients show elevated Th17 and Th1 frequencies and altered cytokine production profiles that are measurable in ex vivo stimulation assays. For programs targeting IL-23, IL-12, IL-17, or upstream signaling nodes, disease-state donor cells provide the relevant baseline biology.
Integrin and homing receptor expression
Lymphocyte trafficking to the gut mucosa is mediated in part by integrin alpha4beta7, the target of vedolizumab. Peripheral blood lymphocytes in IBD patients show distinct integrin expression patterns and activation states compared to healthy donors. For programs developing trafficking inhibitors or gut-selective biologics, IBD donor PBMCs provide the relevant cell populations.
Regulatory T cell deficiency
Treg suppressive function is impaired in IBD, contributing to the failure to maintain mucosal tolerance. Peripheral blood Treg frequencies and suppressive capacity differ between active and remission IBD and between responders and non-responders to current therapies. For Treg-directed therapeutic approaches, IBD donors provide the disease-relevant context.
JAK-STAT signaling
JAK inhibitors (tofacitinib, upadacitinib, filgotinib) are approved for IBD. Understanding the JAK-STAT pathway in IBD patient immune cells — baseline phosphorylation state, cytokine-induced signaling responses, and how JAK inhibition affects specific cytokine pathways — requires disease-state donor cells for pharmacodynamic characterization.
Crohn’s vs. Ulcerative Colitis: Immune Distinctions
Crohn’s disease and ulcerative colitis share the IBD umbrella but differ in immune biology. Crohn’s is a transmural, Th1/Th17-dominant disease affecting any part of the GI tract. Ulcerative colitis is a mucosal disease with a more Th2-weighted immune profile affecting the colon. Peripheral blood immune cell phenotypes differ between the two conditions, and researchers studying mechanism-specific therapeutic targets should specify which IBD subtype is required.
OrganaBio maintains donors from both Crohn’s disease and ulcerative colitis. Contact the scientific team to specify which subtype is needed for your application.
Clinical Annotation
IBD/Crohn’s donors from OrganaBio include:
- Confirmed diagnosis (Crohn’s disease vs. ulcerative colitis, diagnostic method)
- Disease activity at time of collection (Harvey-Bradshaw Index or clinical characterization for Crohn’s; Mayo score or equivalent for UC)
- Disease location and behavior (for Crohn’s: Montreal classification — L1/L2/L3, B1/B2/B3)
- Current therapy and prior biologic history (biologic-naive, biologic-experienced, specific agents)
- Remission vs. active disease status
- Disease duration and relevant surgical history
Biologic-naive donors in active disease preserve the intact disease immune phenotype. Biologic-experienced donors (including patients who have failed one or more mechanisms) are available for studies modeling the refractory patient population.
Available Products and Ordering
IBD/Crohn’s donor material is available in cryopreserved format. Standard product is whole PBMC fraction from mononuclear cell isolation. All material is for research use only.
Contact OrganaBio’s scientific team to discuss IBD subtype, disease activity, treatment history, and cell count requirements. Inventory and availability vary; custom collections can be arranged for specific clinical parameters.
Source from OrganaBio
FDA-registered. ISO 7 cGMP. Ships anywhere in the US.
Request Disease-State PBMCsView PBMC ProductsFrequently Asked Questions
Why are PBMC donors with IBD or Crohn’s disease used in gut immunology and drug development research?
Inflammatory bowel disease (IBD) — including Crohn’s disease and ulcerative colitis — involves dysregulated mucosal immunity with systemic immune activation reflected in peripheral blood. IBD donor PBMCs are used for: studying Th1/Th17 immune dysregulation relevant to IL-12/23 and TNF-α pathway research, evaluating drug candidates targeting JAK-STAT signaling (tofacitinib analogs, upadacitinib), assay development for biologics targeting IL-12, IL-23, IL-17, and integrin α4β7, and understanding how the systemic immune compartment differs between IBD patients and healthy controls across treatment states. For drug development programs targeting cytokine pathways relevant to IBD, primary patient PBMCs provide the most clinically relevant cellular substrate.
Which T cell subsets are most clinically relevant in Crohn’s disease donor PBMCs?
In Crohn’s disease, key T cell populations include: Th1 cells (IFN-γ producing, IL-12-driven, elevated in Crohn’s versus healthy donors), Th17 cells (IL-17A/F producing, IL-23-driven, relevant to anti-IL-17 and anti-IL-23 drug programs), regulatory T cells (Tregs, altered in IBD — whether they are functionally suppressive or pro-inflammatory depends on the cytokine environment), and CD8+ effector T cells with mucosal homing markers. In peripheral blood specifically, elevated Th1 and Th17 frequencies and altered Treg function are the most reproducible findings relative to healthy donors. When ordering Crohn’s donor PBMCs, specifying which T cell subset is the primary readout allows OrganaBio to provide donors with relevant population frequency data.
How is disease activity at collection documented for IBD donors?
OrganaBio documents disease activity for IBD donors using clinically validated scores where available: Harvey-Bradshaw Index or CDAI range for Crohn’s disease, and Mayo Score for ulcerative colitis. Clinical annotation also includes current biologic therapy status (anti-TNF, anti-integrin, anti-IL-12/23, JAK inhibitor, or biologic-naive), time since last dose, prior surgical history (bowel resection, ileostomy status), and relevant comorbidities. For researchers who need donors at a specific disease activity state — active disease versus clinical remission — specifying the desired activity range at the time of ordering allows OrganaBio to select appropriate donors from the annotated pool.
Are biologic-naive IBD donors available and why would a researcher want them?
Yes. Biologic-naive IBD donors — those who have active disease but have not received any biologic therapy — represent a distinct immune profile from patients whose disease is managed on anti-TNF or anti-integrin therapy. Biologic-naive donors have a purely disease-driven immune profile, without the downstream modulation of cytokine pathways produced by chronic biologic exposure. For drug discovery programs evaluating new mechanisms targeting TNF-α or integrin pathways, biologic-naive donors provide a more interpretable baseline signal — you are measuring the drug’s effect on a disease-relevant profile that has not already been partially corrected by a competing mechanism. Biologic-exposed donors are appropriate when the research question involves therapy resistance, secondary failure, or combination drug effects.
Can Crohn’s disease donor PBMCs be used as research material for GI immunology assays?
Crohn’s disease donor PBMCs are appropriate for a range of GI immunology and drug development research assays — including cytokine stimulation assays measuring Th1/Th17 output, flow cytometry panels for T cell subset and activation state characterization, functional assays measuring regulatory T cell suppressive capacity, and in vitro drug screening assays testing JAK inhibitor or cytokine pathway antagonist activity on primary patient cells. Peripheral blood PBMCs reflect systemic immune activation in IBD but do not provide mucosal tissue access — for assays requiring lamina propria or intraepithelial lymphocytes, tissue samples are required. For the systemic immune compartment, Crohn’s donor PBMCs are a well-established and biologically relevant research tool.
